We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA扩大teplizumab适应症至1岁及以上儿童。首款能够在临床前阶段将糖尿病延缓数年的药物。了解输注如何改变婴儿的预后。
